Bull, Bear & Beyond – OSE Immunotherapeutics: executive interview

In this interview, Silvia Comis MD, chief clinical and medical research officer at OSE Immunotherapeutics, covers the company’s lead immuno-oncology candidate, Tedopi. She outlines the current unmet need in non-small cell lung cancer, as well as Tedopi’s clinical track record to date. She also discusses the ongoing registrational Phase III ARTEMIA programme, alongside several other Phase II programmes in different indications run by various academic groups. She concludes by highlighting the key upcoming catalysts and milestones that investors should watch out for.

Listen on your preferred podcast player below:

• Apple Podcast
• Spotify
• YouTube
• Zencastr

About Bull, Bear & Beyond: Each episode features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets and 60-second pieces are a compressed summary of content designed to convey our message in a single, easily shareable hit.